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Trichomonas vaginalis causes vaginitis and increases the risk of HIV transmission by het-
erosexual sex, while Tritrichomonas foetus causes premature abortion in cattle. Our goals
were to determine the effects, if any, of anti-retroviral lectins, which are designed to prevent
heterosexual transmission of HIV, on adherence of Trichomonas to ectocervical cells and
on Tritrichomonas infections in a mouse model. We show that Trichomonas Asn-linked gly-
cans (N-glycans), like those of HIV, bind the mannose-binding lectin (MBL) that is part of the
innate immune system. N-glycans of Trichomonas and Tritrichomonas bind anti-retroviral
lectins (cyanovirin-N and griffithsin) and the 2G12 monoclonal antibody, each of which
binds HIV N-glycans. Binding of cyanovirin-N appears to be independent of susceptibility to
metronidazole, the major drug used to treat Trichomonas. Anti-retroviral lectins, MBL, and
galectin-1 cause Trichomonas to self-aggregate and precipitate. The anti-retroviral lectins
also increase adherence of ricin-resistant mutants, which are less adherent than parent
cells, to ectocervical cell monolayers and to organotypic EpiVaginal tissue cells. Topical
application of either anti-retroviral lectins or yeast N-glycans decreases by 40 to 70% the
recovery of Tritrichomonas from the mouse vagina. These results, which are explained by a
few simple models, suggest that the anti-retroviral lectins have a modest potential for pre-
venting or treating human infections with Trichomonas.
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Introduction
Trichomonas vaginalis is a widely prevalent sexually transmitted human parasite, while Tritri-
chomonas foetus (used in a mouse model of Trichomonas infection) is a widely prevalent sexu-
ally transmitted parasite of cattle [1–3]. While there is a second species that colonizes the
upper digestive track of birds (Trichomonas gallinae) and growing evidence for a two-type
structure to clinical isolates of Trichomonas vaginalis, we will use “Trichomonas” to refer to lab
strains and clinical isolates studied here [4]. Trichomonas, which infects nearly four million
women in the US each year, causes vaginitis, increases the risk of miscarriage, and increases
rates of transmission of HIV from men to women [5–8]. Trichomonas infections are treated by
systemic administration of metronidazole (also known as Flagyl) or tinidazole (Tindamax).
However, ~4% of clinical isolates of Trichomonas show reduced in vitro susceptibility to metro-
nidazole, and adequate safety data are not available regarding the use of tinidazole in preg-
nancy [9]. While there is no vaccine against Trichomonas, numerous candidate antigens have
been identified (reviewed in [10]). Although there is no topical reagent approved to reduce the
likelihood of Trichomonas infection, anti-poly-N-acetyl-glucosamine (PNAG) antibodies and
Sapindus saponins have been proposed [11,12].
Trichomonas causes vaginitis when it penetrates the mucus layer, binds to and lyses ectocer-
vical cells, and migrates across host tissues [13,14]. Trichomonas changes from a flagellated to
an ameboid form, which is associated with changes in gene expression, actin polymerization,
and release of exosomes that fuse with host cells and cause the release of cytokines [15–18].
Adherence to and lysis of a benign prostatic hyperplasia cell line by Trichomonas are by similar
mechanisms, while a Trichomonas homolog of macrophage inhibition factor may cause pros-
tatic cell growth and inflammation [19].
As has been shown for bacteria and other parasites, sugars on the surface of Trichomonas
and host lectins that recognize these sugars are involved in adhesion and pathogenesis [20,21].
Adhesion of Trichomonas to human ectocervical cells in vitro is inhibited by parasite lipoglycan
(LG) that contains chains N-acetyllactosamine (LacNAc), which is galactose linked ß1-4 to N-
acetylglucosamine (GlcNAc). LacNAc is also bound by galectin-1, a component of the innate
immune response that is present in serum, in vaginal secretions, and on the surface of vaginal
epithelial cells [22,23]. Mutants of Trichomonas that do not bind ricin B chain (i.e. are ricin-
resistant) have decreased LacNAc in their LG, show decreased adherence to and lysis of ecto-
cervical cells in vitro, and show decreased binding of host galectin-1 [24]. In addition, the plant
lectin Concanavalin A inhibits adherence of Trichomonas to cell culture monolayers [25].
We have made a number of basic observations concerning the Asn-linked glycans (N-gly-
cans) of Trichomonas. The parasite N-glycan precursor contains seven sugars (Man5GlcNAc2-
PP-dolichol) rather than the 14-sugar precursor (Glc3Man9GlcNAc2-PP-dolichol) made by
most animals, plants, and fungi [26]. The Trichomonas N-glycan is glucosylated by a uridine
diphosphate glucose (UDP-Glc) glucosyltransferase that is part of the N-glycan-dependent
quality control (NG-QC) of glycoprotein folding [27]. Conversely, the Trichomonas N-glycan
is trimmed by an ER mannosidase that resembles those involved in N-glycan-dependent ER-
associated degradation (NG-ERAD) of misfolded glycoproteins. There is positive selection for
sites of N-linked glycosylation in secreted and membrane proteins of Trichomonas and other
eukaryotes with NG-QC [28].
Trichomonas glycoproteins that contain N-glycans or N-glycan sites, which were identified
by mass spectrometry, include important virulence factors shared with Tritrichomonas, as
well as many unique proteins that appear to be absent from the predicted proteins of Tritri-
chomonas (our unpublished data and [29]). Shared virulence factors suggest Tritrichomonas,
which causes a robust vaginal infection in mice that ascends into the uterus, may be a good
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surrogate for Trichomonas [2]. In contrast, Trichomonas causes transient and weak mouse
infections that depend upon inducing estrus, treatment with dexamethasone, and co-infection
with Lactobacilli [3].
Many Trichomonas N-glycans are not processed in the ER or Golgi and so have a single
mannose arm that is similar to the three mannose arms present on unprocessed N-glycans on
gp120 of HIV [26,30,31]. In contrast, most human N-glycans are extensively processed in the
ER and Golgi and contain LacNAc arms capped by sialic acid, as well as fucose attached to
GlcNAc at the base [32]. The unprocessed N-glycans of HIV bind mannose-binding proteins
of the innate immune response, which include the mannose-binding lectin (MBL) in serum
and vaginal secretions, the mannose receptor on macrophages, and DC-SIGN on dendritic
cells [33–36]. MBL, which has a carbohydrate recognition domain and a collagenous domain,
forms oligomers that activate complement by the lectin-mediated pathway. The unprocessed
N-glycans of HIV are also the target of a broadly neutralizing monoclonal antibody (2G12)
derived from a long-term non-progressor infected with HIV, as well as anti-retroviral lectins
(cyanovirin-N from a cyanobacterium and griffithsin from a red alga) developed as topical
therapeutics to prevent the heterosexual spread of HIV [37–40]. These anti-retroviral lectins
are also active against herpes simplex virus (HSV), hepatitis C virus (HCV), and influenza
virus [41–43].
The first goal of our studies was to explore the role, if any, of Trichomonas N-glycans on
pathogenesis. To do this, we determined whether recombinant human MBL labels the surface
of Trichomonas. The specificity of MBL for Trichomonas N-glycans was shown by use of a
morpholino to the Alg7 gene that encodes the first step in synthesis of the N-glycan precursor.
We determined whether MBL, as well as galectin-1, agglutinates flagellated Trichomonas that
are swimming in solution. We tested the effect of topical application of N-glycans from the Sac-
charomyces mnn1/mnn4 double knockout, which makes N-glycans similar to those of Tricho-
monas and HIV, on the recovery of Tritrichomonas in the mouse vagina [44].
The second goal was to determine what effect, if any, anti-retroviral lectins designed as topi-
cal reagents to prevent heterosexual spread of HIV have on Trichomonas in vitro and Tritricho-
monas in the mouse vaginal model. We used flow cytometry to measure the binding of
cyanovirin-N to Trichomonas treated with tunicamycin or an Alg7 morpholino, and we deter-
mined whether N-glycans from the Saccharomyces mnn1/mnn4 double knockout inhibit bind-
ing of cyanovirin-N to parasites. We compared the binding of cyanovirin-N to metronidazole-
sensitive and metronidazole–resistant clinical isolates of Trichomonas axenized at the Center
for Disease Control and Prevention (CDC) [9]. We tested the effects of cyanovirin-N and grif-
fithsin on self-agglutination by Trichomonas and on adherence of the parasite to an ectocervi-
cal monolayer and to organotypic EpiVaginal tissue cells [45,46]. Finally, we measured the
effects of topical application of these anti-retroviral lectins, as well as the 2G12 monoclonal
antibody and galectin-1, on recovery of Tritrichomonas in the mouse vaginal model.
Materials and Methods
Ethics Statement
Culture of Trichomonas and Tritrichomonas has been approved by the Boston University Insti-
tutional Biosafety Committees at Boston University and the University of California-Los Ange-
les. Mouse infections with Tritrichomonas were performed under ABSL-2 protocols (AN-
15352) with the approval of the Boston University Institutional Animal Care and Use Commit-
tee (BU IACUC). Use of metronidazole-resistant and metronidazole–sensitive Trichomonas,
which were previously axenized from de-identified clinical isolates at the CDC, has been
reviewed by the Boston University Institutional Review Board and judged to not be human
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subjects research. The organotypic EpiVaginal tissue cells, which derive from de-identified hys-
terectomy specimens, are a catalog item fromMatTek Corporation (Ashland, MA).
Parasites and cervical/vaginal cell preparations
The genome project G3 strain of Trichomonas, the parental strain (B7RC2) for the ricin-resis-
tant mutants, and the two mutants (4–12 and 2E2) have all been described previously [24,47].
The D1 strain of Tritrichomonas was received from Lynnette Corbeil of UCSD [2]. Metronida-
zole-sensitive and metronidazole-resistant Trichomonas were axenized (grown without bacte-
ria) from clinical isolates at the CDC [9,48]. Parasites were cultured axenically in TYI-S-33
medium containing 10% bovine serum [49]. Human ectocervical cell line (Ect1 E6/E7), which
was a generous gift from Dr. Raina Fichorova of the Brigham and Women’s Hospital, Boston
MA, was grown in defined medium, as previously described [24,45]. Organotypic EpiVaginal
tissue cells were maintained in DMEMmedium containing 10% serum [46].
Microscopy, flow cytometry, and agglutination assays of lectins bound to
the surface of Trichomonas
Logarithmic-phase trophozoites were concentrated by low speed centrifugation and washed in
chilled phosphate buffered saline (PBS). Cyanovirin-N-labeled trophozoites were washed three
times in chilled PBS and then fixed for 10 min at 4°C in 2% paraformaldehyde in 100 mM
phosphate, pH 7.4. Cyanovirin-N and griffithsin (1 μg per 100 μl PBS), as well as the anti-2G12
monoclonal antibody made in plants (0.1 μg per 100 μl PBS) (a generous gift of Kevin Whaley
of Mapp Biopharmaceutical, San Diego, CA), were labeled with Alexa Fluor dyes and then
incubated with intact trophozoites and washed, as described for cyanovirin-N. Recombinant
MBL (from Sigma-Aldrich, USA) were also labeled with Alexa Fluor dyes and incubated with
intact trophozoites. Nuclei were stained with 0.1 μg/ml DAPI, and organisms were visualized
with a DeltaVision deconvoluting microscope (Applied Precision, Issaquah, WA). Images were
taken at 100 X primary and deconvolved using Applied Precision’s softWoRx software.
Measurement of the relative amount of cyanovirin-N to Trichomonas was performed using
a BD FACSCalibur flow cytometer (BD Biosciences, Woburn, MA). The specificity of binding
of cyanovirin-N to N-glycans was determined in three ways. First, we compared the amount of
lectin bound to untreated Trichomonas versus Trichomonas grown for two days in the presence
of 1 μg/ml tunicamycin, which inhibits the phosphoglucosyltransferase (encoded by the Alg7
gene) that catalyzes the first step in N-glycan precursor synthesis [26]. Second, trichomonads
were electroporated with a morpholino to Alg7 gene (ACTCTTGTTGACATATTTGATT
GTT) and then cultured for one day prior to labeling with cyanovirin-N, using methods similar
to those for morpholino knockdowns in Giardia [50]. Third, a Saccharomyces mnn1/mmn4
double-knockout was made [44]; yeast were broken and walls were purified; and N-glycans
were released from yeast walls with PNGaseF. The binding of cyanovirin-N to Trichomonas
+/- yeast N-glycans was then measured using flow cytometry. Similar methods were used to
measure binding of recombinant MBL to Trichomonas. Each flow experiment was repeated
three times.
Agglutination by host MBL and galectin-1 or by anti-retroviral lectins (cyanovirin-N and
griffithsin) was performed by incubating log-phase Trichomonas (12 X 104 parasites in 200 μl
of TYMmedium without serum and antibiotics) with 2.5 μg of lectin for 60 min at 37°C. In
this assay, control Trichomonas incubated without lectin (control group) are flagellated and
swimming, so that they are evenly distributed between four equal 50 μl volumes collected from
top to bottom of the tubes. In contrast, Trichomonas agglutinated by the lectins precipitate to
the bottom of the tube. The experiment was performed in duplicate and repeated twice.
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Adherence of Trichomonas to ectocervical cells and to organotypic
EpiVaginal tissue cells
For ectocervical cell assays, parental strain and ricin-resistant Trichomonasmutants were
labeled with 10 μMCellTracker Blue CMAC (Invitrogen) and incubated with no lectin or with
cyanovirin-N or 1 μg/ml griffithsin (each 1 μg per 100 μl PBS). Parasites (~100,000 per 500 μl
PBS) +/- lectins were allowed to adhere to ~300,000 ectocervical cells grown to confluence on a
coverslip in a 24 well plate [24]. After 30 min at 37°C coverslips were washed x 4 in PBS to
remove nonadherent parasites, fixed in 4% paraformaldehyde, and mounted on slides. Fluores-
cenated Trichomonas present in fifteen 20X fields were counted using Scion Image for Win-
dows. Each treatment was performed in triplicate, and each experiment was performed at least
three independent times.
For organotypic EpiVaginal tissue cell assays, logarithmic phase parental strain and ricin-
resistant Trichomonasmutants were labeled with 10 μMCellTracker green (CMFDA) for 5 min
at RT (Invitrogen). CMFDA is concentrated in cytoplasmic vesicles of Trichomonas. Some
Trichomonas trophozoites were also labeled with cyanovirin-N conjugated to Alexa Fluor 594
(1 μg per 100 μl PBS). Trichomonads were washed, resuspended in culture medium without
serum, and incubated with EpiVaginal tissue cells for 60 min at 37°C under anaerobic condi-
tions. Three washes in PBS were used to remove unbound parasites from EpiVaginal tissue cells,
which were fixed in 2% paraformaldehyde, mounted on a two-chambered cover glass system
(Thermo Fisher Scientific, WalthamMA), and observed with the deconvoluting microscope.
Infections of mice with Tritrichomonas
Six weeks old female BALB/c mice were purchased from Taconic (Hudson, NY). Five mice per
treatment were infected vaginally with 500 parasites in 10 μl medium +/- 5 μg cyanovirin-N,
griffithsin, 2G12 monoclonal antibody, or galectin-1 [2]. Alternatively, Tritrichomonas was
infected vaginally with N-glycans released from Saccharomyces mnn1/mmn4 double-knockout.
After two days 100 μl PBS was used to wash out Tritrichomonas parasites, which were incu-
bated overnight in TYMmedium to release organisms from viscous vaginal secretions. Para-
sites were fixed and counted. Each experiment was repeated at least three times.
Results
Effects of host mannose-binding lectin and yeast N-glycans on
Trichomonas in vitro and Tritrichomonas in mice
Our hypothesis here is that host MBL, which binds to unmodified N-glycans of HIV, will also
bind to unmodified N-glycans on Trichomonas (Fig 1A) [33–36]. In support of this idea, we
found that recombinant MBL binds to the surface of Trichomonas (Fig 1B). The non-homoge-
neous binding of MBL (and of anti-retroviral lectins in Figs 2A, 3A, 3B and 4B) is likely subse-
quent to the ridged and ruffled surface of trichomonads labeled in solution. The specificity of
the binding of MBL to unmodified Trichomonas N-glycans was shown by decreased binding of
MBL to Trichomonas pre-treated with an Alg7 morpholino, which decreases expression of the
enzyme that is the first step in N-glycan precursor synthesis (Fig 1C) [26]. Trichomonads,
which are flagellated and swim as individuals in solution, are agglutinated by MBL and sink to
the bottom of a test tube (Fig 2B and 2C). These aggregates resemble “swarms” of Trichomonas
formed in response to stress [51]. Similarly, recombinant galectin-1, which binds to the surface
of Trichomonas [22], also causes flagellated trichomonads to self-aggregate and precipitate.
Because Trichomonas weakly infects mice while Tritrichomonasmakes a robust infection
that ascends into the uterus, Tritrichomonas was used to explore the possible role for parasite
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N-glycans in pathogenesis [2,3]. Tritrichomonas was directly applied to the mouse vagina +/-
N-glycans from a Saccharomyces mnn1/mnn4 double knockout, which makes N-glycans simi-
lar to those of Trichomonas and HIV [44]. These yeast N-glycans, which have been used to
raise antibodies targeted to the N-glycans present on gp120 of HIV, decreased recovery of Tri-
trichomonas by 40% (P< 0.001) after two days in the mouse vaginal model (Fig 1D). Because
we did not perform a histological examination of the vagina nor are we detecting luciferase
expressing parasites by bioluminescence, we cannot rule out that some adherent parasites
remain after the vaginal wash. Alternatively, some Tritrichomonasmay have migrated to the
uterus and were not counted.
Anti-retroviral lectins and the 2G12 monoclonal antibody bind N-glycans
of Trichomonas.
The anti-retroviral lectins cyanovirin-N and griffithsin and the anti-carbohydrate 2G12 mono-
clonal antibody bind to the surface of Trichomonas and Tritrichomonas (Figs 2A, 3A, 3B and
4B) [37–40]. The specificity of cyanovirin-N for Trichomonas N-glycans was shown in two
ways [30]. First, treatment of Trichomonas with an Alg7 morpholino or with tunicamycin,
both of which target the first enzyme in N-glycan precursor synthesis, decreases binding of
Fig 1. Mannose-binding lectin (MBL) binds to unprocessedN-glycans on the surface of Trichomonas.
A. MBL, as well as anti-retroviral lectins (cyanovirin-N and griffithsin) and 2G12 monoclonal antibody, binds to
the single mannose arm (red box) of an unprocessed N-glycan of Trichomonas. B. MBL (green) labels the
surface of Trichomonas. The nucleus is labeled with DAPI. C. Flow cytometry shows that labeling with the
MBL (red) is decreased when Trichomonas is treated with an Alg7 morpholino (green) that decreases
synthesis of theN-glycan precursor. Unlabeled parasites are shown in black. D. N-glycans from the
Saccharomyces mnn1/mmn4 double-knockout decrease by 40% the recovery after two days of
Tritrichomonas in the vagina of mice (average of three experiments with five mice each).
doi:10.1371/journal.pone.0135340.g001
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cyanovirin-N to the parasites, as measured by flow cytometry (Fig 3C) [26,50]. Second, binding
of cyanovirin-N is inhibited by co-incubation with N-glycans released from a Saccharomyces
mnn1/mmn4 double-knockout (Fig 3D) [44]. As a control for the adherence experiments (see
below), we showed that binding of cyanovirin-N is slightly greater to ricin-resistant mutants
(2E2 and 4–12) than to the parent strain (B7RC2) (Fig 3E) [24].
We tested the binding of cyanovirin-N to axenized clinical isolates of Trichomonas from the
CDC, which are either sensitive to metronidazole (two isolates) or resistant to metronidazole
(five isolates) [9,48]. All but one of the clinical isolates binds cyanovirin-N better than the par-
ent strain (B7RC2) for the ricin-resistant mutants (Fig 3F). The two clinical isolates that bind
cyanovirin-N best include one isolate that is metronidazole-sensitive and one that is metroni-
dazole-resistant. These results suggest N-glycan synthesis and metronidazole activation are
unrelated, and so anti-retroviral lectins might be used as an additional, local treatment for met-
ronidazole-resistant Trichomonas or for pregnant women, who cannot take tinidazole.
Effects of anti-retroviral lectins on Trichomonas in vitro and
Tritrichomonas in mice
Like MBL and galectin-1, anti-retroviral reagents (cyanovirin-N, griffithsin, and the 2G12
monoclonal antibody) each cause flagellated trichomonads to self-aggregate and precipitate
(Fig 2A and 2B). Previous studies have shown that ricin-resistant mutants of Trichomonas
Fig 2. Host lectins (galectin-1 and MBL), as well as anti-retroviral lectins (cyanovirin-N and griffithsin)
and 2G12monoclonal antibody, agglutinate flagellated Trichomonas and cause them to precipitate. A.
Fluorescence micrograph of Trichomonas aggregated by griffithsin (green). Nuclei are labeled with DAPI. B.
In the absence of host or exogenous lectins added to TYMmedium (control group), flagellated Trichomonas
parasites swim and remain in roughly equal numbers in the top (purple), middle (green and rust), and bottom
(blue) 50 μl fractions of a 200 μl suspension. In contrast, host MBL and galectin-1 (Gal-1), as well as
exogenous cyanovirin-N (CVN) and griffithsin (GFTH), agglutinate swimming Trichomonas and cause them
to precipitate, so that the vast majority of the parasites are in the bottom 50 μl fraction (blue). The average of
two experiments, each performed in duplicate, with very similar results is shown. C. Model shows that host or
exogenous lectins agglutinate flagellated Trichomonas and cause them to precipitate (blue arrow).
doi:10.1371/journal.pone.0135340.g002
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adhere less well than the parental strain to ectocervical cells in vitro and that galectin-1
increases adherence [22,24]. Here we found that cyanovirin-N nearly doubles the adherence of
ricin-resistant mutants to ectocervical cells, while griffithsin has a more modest effect on
adherence (Fig 4A). In contrast, neither of the anti-retroviral lectins have much effect on
adherence of the parent strain (B7RC2), which adheres well to ectocervical cell monolayers in
the absence of lectins.
Close examination of Trichomonas adhering to organotypic EpiVaginal tissue cells, which
form a multilayered squamous epithelium that closely resembles that of the vagina [46],
showed three findings. First, cyanovirin-N increases adherence to EpiVaginal cells of ricin-
resistant mutants, as was shown with ectocervical cell monolayers (data not shown). Second,
cyanovirin-N binds well to EpiVaginal cells, which have unprocessed N-glycans on their sur-
face in addition to complex N-glycans that do not bind cyanovirin-N (Fig 4C). Third, when
trichomonads adhere to the EpiVaginal cells and transform from a flagellated to an ameboid
form, they shed most of the cyanovirin-N that is present on swimming parasites (Fig 4B and
4C). Although cyanovirin-N agglutinates flagellated parasites and causes them to sink to the
bottom of a tube or flask (Fig 2B and 2C), cyanovirin-N and the other lectins that bind to
Fig 3. Anti-retroviral lectins and the 2G12monoclonal antibody bindN-glycans of Trichomonas. A.
Fluorescence micrographs show binding of griffithsin 2G12 antibody (red) to the surface of Trichomonas. B.
Fluorescence micrograph shows binding of cyanovirin-N to the surface of Tritrichomonas. C. Flow cytometry
shows that labeling with cyanovirin-N (green) is decreased when Trichomonas is treated with an Alg7
morpholino (red) or treated with tunicamycin (blue), both of which inhibit the first step in synthesis of the N-
glycan precursor. D. Flow cytometry shows decreased binding of cyanovirin-N to Trichomonas (green) in the
presence of N-glycans from the Saccharomyces mnn1/mmn4 double-knockout (red). E. Flow cytometry
shows binding of cyanovirin-N to ricin resistant mutants (2E2 and 4–12) is slightly greater than binding to
parent strain (B7RC2). F. Flow cytometry shows that binding of cyanovirin-N to two metronidazole-sensitive
clinical isolates (bright blue and tan) and five metronidazole-resistant clinical isolates (green, dark blue, light
blue, brown, and purple) from the CDC is as great or greater than binding of cyanovirin-N to B7RC2 (red), the
parent strain for the ricin-resistant mutants.
doi:10.1371/journal.pone.0135340.g003
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Trichomonas do not cause them to convert to an ameboid form, which only occurs when
trichomonads adhere to host cells or to a derivatized surface [13–18,22,24,25].
Topical application of cyanovirin-N or griffithsin at the time of infection with Tritrichomo-
nas reduced the recovery of parasites from the vagina of mice after two days by 63% or 70%,
Fig 4. Anti-retroviral lectins increase the adherence of ricin-resistant Trichomonasmutants to ectocervical cells, while cyanovirin-N is lost from
the parasite surface when Trichomonas binds to EpiVaginal tissue cells and converts into an ameboid form. A. Cyanovirin-N (CVN) increases the
adherence of ricin-resistant mutant Trichomonas (2E2 and 4–12) to ectocervical cells in vitro, while griffithsin (GRFT) has less effect. Neither lectin has much
effect on the parent B7RC2 strain, which is much more adherent to ectocervical cells in the absence of lectin. Data is average of three experiments. B. A
flagellated Trichomonas labeled green with CMFDA (green), which concentrates in secretory vesicles, has cyanovirin-N (red) on its surface. C. When
CMFDA-labeled Trichomonas adhere to organotypic EpiVaginal tissue cells, most of the cyanovirin-N is lost. Note that the host EpiVaginal cell (lower left)
binds cyanovirin-N. D. A model for how host lectins affect adherence of Trichomonas to host cells is based upon experiments here and previously published
experiments [24]. Galectin-1 (purple) secreted by the host epithelial cells cross-links LacNAc residues (bright blue) present on glycans of host proteins (grey)
and on parasite LG (bright green). Similarly, host mannose-binding lectin (deep green) cross-links unmodifiedN-glycans (red) present on host and parasite
proteins. E. Exogenous anti-retroviral lectins (brown) cross-link N-glycans on the surface of Trichomonas and host cells.
doi:10.1371/journal.pone.0135340.g004
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respectively (Fig 5). Although the 2G12 monoclonal antibody had little effect on the recovery
of Tritrichomonas from the mouse vagina, galectin-1 reduced recovery by 51% (Fig 5). These
results, which have the same caveats as experiments with the yeast N-glycans with regards to
missing adherent parasites or those that have migrated to the uterus, suggest anti-retroviral lec-
tins have a modest potential for treating or preventing human infections with Trichomonas.
Discussion
Revised models for Trichomonas adherence and pathogenesis
Previous studies showed that adherence of Trichomonas to ectocervical cells is mediated in
part by host galectin-1, which is bivalent and binds to LacNAc on parasite LG and to LacNAc
on host cells (Fig 4D) [22–24]. The present experiments show that galectin-1 agglutinates flag-
ellated Trichomonas, so they are less able to swim and divide (Fig 2B and 2C). In contrast,
galectin-1 decreases recovery of Tritrichomonas in the mouse vaginal model (Fig 5). This dis-
crepancy, which is also the case for the anti-retroviral lectins, suggests the importance of the in
vivomodel, even if it is with the bovine rather than the human parasite and even if there is a
possibility that all parasites have not been obtained in the washes [2,3].
MBL, another important player in the host innate immune response, binds to unmodified
N-glycans on the surface of Trichomonas and causes parasites to self-aggregate (Figs 1A–1C,
2B and 2C) [33–36]. Whether complement activation by MBL plays a role in Trichomonas
infections was not examined. Recovery of Tritrichomonas in the mouse vaginal model is
decreased in the presence of N-glycans from the Saccharomyces mnn1/mmn4 double-knockout
(Fig 1D) [44]. This result suggests roles for N-glycans of the host and/or parasite in coloniza-
tion of trichomonads in vivo.
The results here, as well as recent experiments that demonstrate roles for parasite exosomes,
bacterial vaginosis, and host cytokines [7,8,13–15,22–24,52], suggest that mechanisms of path-
ogenesis by Trichomonas are multiple and complex. Similarly, how anti-retroviral lectins
reduce recovery of Tritrichomonas in vivo (next section) is likely more complicated than how
these same reagents block invasion of HIV invasion into host cells [37–40,53].
Modest potential for anti-retroviral lectins to prevent Trichomonas
infections
The logic for testing anti-retroviral lectins versus Trichomonas included the following. Spectro-
metric studies show that many Trichomonas surface and secreted proteins have no known
function and are unique to the parasite, so it is difficult to choose vaccine candidates (our
unpublished data and [29]). The majority of unique Trichomonas proteins are absent from the
predicted proteins of Tritrichomonas (our unpublished data), so that it is necessary to overex-
press the Trichomonas vaccine candidate in transformed Tritrichomonas and then use these
parasites in the mouse model [2,3,54]. In contrast, nearly all Trichomonas surface and secreted
proteins have N-glycan sites. Like HIV and HSV, Trichomonas is sexually transmitted, so an
anti-retroviral reagent present in the vagina might be used to prevent all three infections
[1,6,37–40]. The big advantage of using the anti-retroviral reagents versus Trichomonas is that
GMP production, pharmacokinetic studies, and toxicity tests, all of which are likely prohibi-
tively expensive for a new anti-trichomonad reagent, will have already been performed in an
effort to prevent heterosexual transmission of HIV [39,40]. Finally, the use of a topical anti-ret-
roviral reagent along with systemic treatment with tinidazole or metronidazole to treat drug-
resistant Trichomonas is similar to the idea of combining anti-retroviral lectins with conven-
tional anti-retroviral drugs to target HIV [55].
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Similar to host galectin-1 [16], anti-retroviral lectins and 2G12 antibody increase adherence
of trichomonads to ectocervical cells in vitro (Fig 4A). This effect is most likely by cross-linking
unprocessed N-glycans on the surface of parasite and host (Figs 3B–3F and 4E). Agglutination
of flagellated parasites by the anti-retroviral lectins may also contribute to their effect on adher-
ence in vitro and colonization in vivo (Fig 2A–2C). While anti-retroviral lectins have been
shown to decrease infectivity of numerous viruses in animal models, this is the first time that
these lectins have been tested versus a parasite in a mouse model (Fig 5) [41–43]. The modest
reduction in Tritrichomonas recovered in the presence of anti-retroviral lectin (with many
caveats about the counting) is much less than the total elimination of parasites that can be
accomplished with metronidazole or tinidazole [9]. Indeed the partial reduction in parasite
recovery is more similar to that seen by vaccination against Trichomonas, Entamoeba, or Giar-
dia [10,56,57]. An alternative conclusion from the studies here is that the use of anti-retroviral
reagents to prevent heterosexual transmission of HIV and HSV is unlikely to have a large nega-
tive effect on Trichomonas infections. Because Trichomonas does not infect easily infect mice,
anti-retroviral lectins might be tested in an excellent but expensive pigtail macaque model of
Trichomonas infection +/- HIV [58–60].
Fig 5. Anti-retroviral lectins decrease recovery of Tritrichomonas in a mouse vaginal model.Recovery of Tritrichomonas after two days in the vagina
of mice shows a modest but statistically significant decrease by co-infection with cyanovirin-N (63% decrease), griffithsin (70% decrease), or galectin-1 (51%
decrease). In contrast, there is little effect of the 2G12 monoclonal antibody. Data is the average of three experiments each containing five mice per
treatment.
doi:10.1371/journal.pone.0135340.g005
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